Abstract
Isatin (indole-dione-2,3) is an endogenous indole that exhibits a wide spectrum of biological and pharmacological activities. Physiologically relevant concentrations of isatin (ranged from 1 nM to 10 μM) did not influence basal activity of soluble human platelet guanylate cyclase (sGC), but caused a bell-shaped inhibition of the NO-activated enzyme. Inhibition of the NO-dependent activation by isatin did not depend on a chemical nature of the NO donors. The inhibitory effects of ODC (a heme-dependent inhibitor of sGC) and isatin were non-additive suggesting that the inhibitory effect of isatin may involve the heme binding domain (possibly heme iron) and experiments with hemin revealed some isatin-dependent changes in its spectrum. Isatin also inhibited sGC activation by the allosteric activator YC-1. It is suggested that the bell shaped inhibition of the NO-dependent activation of sGC by isatin may be attributed to complex interaction of isatin with the heme binding domain and the allosteric YC-1-binding site of sGC.
Similar content being viewed by others
References
Medvedev, A.E., Clow, A., Sandler M., and Glover, V., Biochem. Pharmacol., 1996, vol. 52, pp. 385–391.
Medvedev, A.E., Igosheva, N., Crumeyrolle-Arias N., and Glover, V., Stress, 2005, vol. 8, pp. 175–183.
Medvedev, A.E., Buneeva, O.A., and Glover, V., Biological Targets Therapeutics, 2007, vol. 1, pp. 151–162.
Glover, V., Medvedev, A.E., and Sandler, M., Life Sci., 1995, vol. 57, pp. 89–94.
Medvedev, A.E., Sandler, M., and Glover, V., Life Sci., 1998, vol. 62, pp. 2391–2398.
Binda, C., Li, M., Hubaler, F., Restelli, N., Edmondson, D.E., and Mattevi, A., Proc. Natl. Acad. Sci. USA, 2003, vol. 100, pp. 9750–9755.
Medvedev, A.E., Bussygina, O.G., Pyatakova, N.V., Glover, V., and Severina, I.S., Biochem. Pharmacol., 2002, vol. 63, pp. 763–766.
Ignarro L.J., Napoli C., and Loscalzo, J., Circ. Res., 2002, vol. 90, pp. 21–28.
Kotz, A.Y., Martin, E., Sharina, I.G., and Murad, F., Hand Exp. Pharmacol., 2009, vol. 191, pp. 1–14.
Hobbs, A.J., Br. J. Pharmacol., 2002, vol. 136, pp. 637–640.
Stasch, J.P. and Hobbs, A.J., Hand Exp. Pharmacol., 2009, vol. 191, pp. 277–308.
Chirkov, Yu.Yu., Tyshchuk, I.A., Belushkina, N.N., and Severina, I.S., Biokhimiya, 1987, vol. 52, pp. 956–963.
Garbers, D.S. and Murad, F., Adv.Cycl. Nucl. Res., 1979, vol. 10, pp. 57–67.
Bradford, H.M., Anal. Biochem., 1976, vol. 72, pp. 248–254.
Bussygina, O.G., Pyatakova, N.V., Khropov, Yu.V., Ovchinnikov, I.V., Makhova, N.N., and Severina, I.S., Biochemistry (Moscow), 2000, vol. 65, pp. 457–462.
Schmidt, K., Schrammel, A., and Koesling, D., Mol. Pharmacol., 2001, vol. 59, pp. 220–224.
Friebe, A. and Koesling, D., Curculat. Res., 2003, vol. 93, pp. 96–106.
Russwurm, M., Mergia, M., Mullershausen, E., and Koesling, D., J. Biol. Chem., 2002, vol. 277, pp. 24883–24888.
Behrends, S., Curr. Med. Chem., 2003, vol. 10, pp. 291–301.
Bellamy, T.C. and Cartwaite, J., Br. J. Pharmacol., 2002, vol. 136, pp. 95–103.
Evgenov, O.V., Pacher, P., Schmidt, P.M., Hasko, G., Schmidt, H.H.H., and Stasch, J.P., Rev. Drug Discov., 2006, vol. 5, pp. 755–768.
Yazawa, S., Tsichiya, H., Hori, H., and Makino, R., J. Biol. Chem., 2006, vol. 281, pp. 21763–21770.
Lamothe, M., Chang, F.J., Balashova, N., Shirokov, R., and Beuve, A., Biochemistry, 2004, vol. 43, pp. 3039–3048.
Medvedev, A.E., Sandler, M., and Glover, V., Eur. J. Pharmacol., 1999, vol. 384, pp. 239–241.
Mandal, P. and Ganguli, T., J. Phys.Chem. B, 2009, vol. 113, pp. 14904–14913.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © I.S. Severina, A.Yu. Schegolev, G.V. Ponomarev, A.E. Medvedev, 2011, published in Biomeditsinskaya Khimiya.
Rights and permissions
About this article
Cite this article
Severina, I.S., Schegolev, A.Y., Ponomarev, G.V. et al. Inhibition of NO-dependent soluble human platelet guanylate cyclase by isatin. Biochem. Moscow Suppl. Ser. B 5, 263–267 (2011). https://doi.org/10.1134/S1990750811030115
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1990750811030115